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Abstract
Background: Niemann–Pick disease type C is a rare metabolic disease characterized by progressive neurological
deterioration with childhood onset, and often results in premature mortality. Niemann–Pick disease type C has an
extremely heterogeneous clinical presentation with a wide range of visceral and neurological signs and symptoms
that are not specific to the disease, and which progress over varied periods of time. The incidence and epidemiology
of Niemann–Pick disease type C in Russia have not been characterized. We report the case of a Russian newborn with
early-infantile onset Niemann–Pick disease type C who displayed prolonged neonatal jaundice and hepatosplenomegaly.
Case presentation: A 5-year-old white boy born to non-consanguineous Russian parents was originally diagnosed
with galactosemia at the age of 2 months based on a raised blood galactose level. A galactose-free and lactose-free
diet resulted in achievement of a normal galactose level, but hepatosplenomegaly and cholestatic signs persisted. Liver
biopsy results hinted at possible Niemann–Pick disease type C, but differential diagnostic investigations for progressive
familial intrahepatic cholestasis type 2 (Byler syndrome) indicated a heterozygous genotype suggestive of this disease.
Further, progressive neurological symptoms prompted additional genetic analyses for possible Niemann–Pick disease
type C, from which an as-yet unreported combination of known NPC1 gene mutations was identified, and a final
diagnosis of Niemann–Pick disease type C was established. The patient subsequently developed typical neurological
symptoms of early-infantile Niemann–Pick disease type C, including vertical supranuclear ophthalmoparesis and
cerebellar ataxia. Miglustat therapy was initiated 2.5 years ago, and some improvements in movement and speech
have since been observed.
Conclusions: This case illustrates the continued challenges associated with diagnosing Niemann–Pick disease type C
based on the appearance of nonspecific cholestatic symptoms. Based on this case we recommend examination of all
newborns and children who display unexplained cholestasis or isolated splenomegaly/hepatosplenomegaly during the
first months of life for other signs of possible Niemann–Pick disease type C.
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Background
Niemann–Pick disease type C (NP-C) is a rare lysosomal
storage disease in which impaired intracellular lipid traffick-
ing leads to excess storage of cholesterol, sphingomyelin,
glycosphingolipids, and sphingosine in the brain, liver,
spleen, lungs, and other tissues [1]. The incidence of NP-C
in Russia has not yet been established; only single case re-
ports have been published to date [2].
NP-C has an extremely heterogeneous clinical presenta-
tion characterized by a wide range of symptoms that are
not specific to the disease, and which arise and progress
over varied periods of time [1, 3]. Disease onset occurs in
the neonatal period in a notable proportion of patients. In
particular, NP-C represents one of the leading metabolic
causes of cholestatic syndrome in babies [3]. Non-immune
hydrops, ascites, and fetal hepatosplenomegaly are also
often described in affected children [3]. Cholestasis and
severe splenomegaly in the absence of portal hypertension
are considered to be pathognomonic [4].
We report the case of a 5-year-old boy with early infant-
ile onset NP-C that illustrates some of the challenges asso-
ciated with diagnosing the disease early on in life based on
the appearance of nonspecific cholestatic symptoms.
Case presentation
The patient was a 5-year-old Caucasian boy (weight at
birth 2900 g, height at birth 50 cm) born to non-
consanguineous parents with no previous medical history
of NP-C in Krasnodar, Russia. Jaundice was observed at
the age of 3 days and was considered physiological. The
child was therefore discharged. However, he was later hos-
pitalized at a child care facility due to continued jaun-
dice and mild hepatosplenomegaly (liver 2.5 cm and
spleen 1 cm), at which point raised total and conjugated
bilirubin, alkaline phosphatase, cholesterol, alanine amino-
transferase (ALT), and aspartate aminotransferase (AST)
were observed.
The results of his hematology and urine analysis tests
were normal, but heightened nervous reflex irritability
was observed. Blood polymerase chain reaction (PCR)
testing for cytomegalovirus (CMV), herpes simplex
virus (HSV), toxoplasmosis, and chlamydia infection
were negative. However, a blood galactose of 12 ng/ml
(upper limit of normal, 7.1 ng/ml) was observed, which
increased to 20 ng/ml at repeat examination. On this
basis, galactosemia was suspected and a galactose-free
and lactose-free diet was prescribed. By the age of
2 months the patient’s blood galactose level was nor-
malized, but cholestasis and hepatosplenomegaly per-
sisted. He was therefore referred to the Research
Center for Obstetrics, Gynecology and Perinatology at
the Federal State Budget Institution in Moscow, Russia
for further work up.
We observed hypotrophy and continued jaundice at our
initial examination: body weight 4100 g (percentile 5 to 10);
height 57 cm (percentile 25). Ongoing hepatosplenomegaly,
cholestasis, and cytolysis were also confirmed, but synthetic
liver function tests and standard metabolic parameters were
all normal (Table 1). There were no signs of portal hyper-
tension in spite of the enlarged spleen (+6.5 cm under the
costal rib). His plasma chitotriosidase was slightly increased
(251.5 nmol/mg/hour, normal range 4.5 to 198 nmol/mg/
hour). Galactosemia was eventually ruled out based on
normal galactose-1-phosphate-uridyl transferase enzyme
levels and genetic testing. Differential diagnoses for an
extensive group of other metabolic and non-metabolic
diseases were eliminated: biliary atresia, Gaucher disease
type 1 (GD1), α-1-antitrypsin deficiency, tyrosinemia,
citrullinemia type 2, progressive familial intrahepatic cho-
lestasis type 3, mitochondrial disorders, Alagille syndrome,
and others.
A liver biopsy revealed swollen Kupffer cells with foamy
cytoplasm, which are considered typical histopathological
hallmarks of NP-C (Fig. 1). A preliminary diagnosis of NP-
C was therefore concluded. No causal NPC2 gene muta-
tions were detected; while parallel investigations for pro-
gressive familial intrahepatic cholestasis type 2 (Byler
syndrome) indicated a heterozygous genotype suggestive of
this disease.
Typical symptoms of Byler syndrome include progressive
cholestasis with low blood gamma glutamyltransferase
(GGT) levels and severe pruritus. Liver transplantation is
always indicated for Byler syndrome because of its associ-
ation with biliary cirrhosis and poor quality of life. During
the examination of our patient at the age of 2 to 3 months
he had slightly increased (near-normal) GGT and he was
too young for pruritus. Pruritus usually appears at the age
Table 1 Blood biochemical analysis at the age of 2 months and
1 week
Parameters Value Normal range
Total bilirubin, mkM/l 223 3.4–21.0
Conjugated bilirubin, mkM/l 117 0–5.5
Gamma glutamine transferase, U/l 73 0–50
Alkaline phosphatase, U/l 730 50–360
Alanine aminotransferase, U/l 313 0–40
Aspartate aminotransferase, U/l 673 0–40
Creatine phosphokinase, U/l 167 0–171
Albumin, g/l 45 35–50
Cholinesterase, U/l 6237 3930–10800
Fibrinogen, g/l 3,9 2–4
Prothrombin time index, % 94 80–120
Lactate, mmol/l 1.1 1.2
Glucose, mmol/l 3.7 3.5–6.4
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of 4 to 5 months or later, which is why we could not
exclude Byler syndrome. On the other hand we could not
insist on the performance of genetic testing for NPC1 in
this case because of the expense involved and the fact that
his family was not ready.
The patient undertook a high medium-chain triglyceride
diet with fat-soluble vitamins, and ursodeoxycholic acid
therapy. Jaundice eventually disappeared by 5 months of
age, and by the age of 2 years his hepatomegaly had re-
solved. His splenomegaly had also decreased (6 to 7 cm).
Later on it became obvious that he did not have Byler syn-
drome as his cholestasis resolved, he did not have pruritus,
and he had splenomegaly without portal hypertension. He
was therefore not indicated for liver transplantation. On
balance, we decided to suspend further genetic testing.
After a bout of acute otitis he stopped walking on his
own aged 2 years and 10 months. He also stopped eating
independently due to a pronounced tremor. Brain MRI
findings were normal. These neurological symptoms
prompted further diagnostic tests for possible NP-C, and
complete NPC1 gene mutation analysis identified an as yet
unreported combination of known mutations c.2777C>T
(p.Ala926Val: CM077214) and c.2196_2197insT.
Retrospective analysis of his neurological status showed
normal psychomotor development during his first year of
life, but he did display minor deficits (for example, inward
turning of his feet, awkward gait) that were probably the
first neurological disease manifestations. An observable
tremor first appeared when he was 2.5-years old.
At the time of reporting he is 5-years old and displays
abnormal saccadic eye movements, trunk ataxia, hypo-
tonia, subcortical cerebellar dysarthria and dysmetria, and
intention tremor. He continues to walk with assistance
but his gait is ataxic-polyneuropathic. He has also lost
2 kg in body weight since the initial onset of neurological
manifestations, and displays signs of first-degree hypotro-
phy. His splenomegaly persists (spleen size, 7 cm).
Miglustat (Zavesca®; Actelion Pharmaceuticals Ltd) was
initiated 2.5 years ago with appropriate dietary alterations.
Positive changes have since been observed, including
reduced tremor and decreased muscle hypotonia. The
patient can sometimes walk without assistance and he
exhibits a degree of improvement in his speech. He has
also gained weight. His liver function test results remain
normal, and splenomegaly has persisted without signs of
portal hypertension.
Discussion
This case report is based on a typical case of early-infantile
onset NP-C, and illustrates some of the challenges associ-
ated with diagnosing patients with NP-C early on in life
based on the appearance of nonspecific cholestatic symp-
toms. Despite the appearance of neonatal cholestasis, which
prompted investigations for possible Gaucher disease (GD)
or galactosemia, neurological signs suggestive of NP-C only
became apparent at the end of the first year of life [1, 3].
Cholestasis and splenomegaly were the first clinical signs
of NP-C in our patient, and NP-C ranks highly among
possible metabolic causes of neonatal cholestasis [3]. Never-
theless, a differential diagnosis was performed in a way that
took into account an extensive group of other metabolic
and non-metabolic diseases, including: GD, galactosemia,
α-1-antitrypsin deficiency, tyrosinemia, citrullinemia type 2,
progressive familial intrahepatic cholestasis type 3, mito-
chondrial disorders, Alagille syndrome, and others.
Swollen Kupffer cells with foamy cytoplasm in liver
biopsy specimens was the first strong sign of NP-C, but
even these histopathological changes are not specific to
the disease [4]. Filipin staining in cultured skin fibro-
blasts is considered a key diagnostic test for NP-C [1, 3],
but it was not applied in our patient due to technical
difficulties. Genetic testing has increasingly been used in
the detection of NP-C over the last decade, particularly
among patients with nonspecific, albeit suggestive, clin-
ical symptoms. In this case, NPC1 mutation analysis was
only applied after the appearance of neurological disor-
ders, and it identified known mutations allowing a full
confirmation of the diagnosis.
NP-C pathognomonic symptoms such as vertical supra-
nuclear ophthalmoparesis, and cerebellar signs such as
ataxia, dysarthria, and dystonia, only became evident 2 years
ago (when our patient was 3-years old). The comprehensive
characterization of the time of onset, nature, and severity of
neurological signs is considered vital for diagnosing NP-C,
but can be very challenging in children below 2 years of age
[3]. A recently developed pediatric version of the NP-C
suspicion index alongside plasma oxysterol testing might
help in this respect, in future cases [5].
Fig. 1 Histopathological liver biopsy findings. Hematoxylin and eosin
staining with magnification ×400 showing swollen Kupffer cells with
foamy cytoplasm, typical for Niemann–Pick disease type C
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Conclusions
A targeted treatment for neurological deterioration that has
been reported to slow disease progression and improve
patients’ quality of life is now available for NP-C [3]. In view
of this case, we consider it important to examine all new-
borns and children who display unexplained cholestasis or
isolated splenomegaly/hepatosplenomegaly during the first
months of life for signs of possible NP-C.
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